Company News-Guangzhou DiQi Pharmaceuticals Co., Ltd

Home

About Us

Technology Platform

Product Center

Service and Support

Collaboration Mode

News

Join Us

News

Company News

Filter:

All years

All years 2017 2018 2019 2020 2021 2022 2023 2024 2025

2025/09/10Minister Long Yongtu Visits DiQi Pharmaceuticals Co., Ltd to Discuss Corporate Development

On September 10, 2025, Mr. Long Yongtu, former Vice Minister of the Ministry of Foreign Trade and Economic Cooperation of China and Chief Negotiator for China's accession to the WTO, currently serving as Co-Chairman of the Global CEO Development Conference and Chairman of the China Center for International Economic Exchanges, visited DiQi Pharmaceuticals Co., Ltd for an exchange.
2025/09/02DiQi Pharma Supports Approval and Market Launch of Morphine Sulfate Extended-Release Tablets and Compound Tropicamide Eye Drops

Golden autumn brings refreshing breezes and frequent good news! Building on its exceptional R&D capabilities and efficient technical services, Guangzhou DiQi Pharmaceuticals Co., Ltd. has achieved another milestone in September. Following the successful development of compound tropicamide eye drops for Shandong Chenxin Pharmaceutical Co., Ltd. in June this year, which secured a production license, the company has now successfully obtained a production license for the morphine sulfate sustained-release tablets project developed for Weihai Lotus Pharmaceutical Co., Ltd.!
2025/05/22DiQi Pharma and Guangzhou Bank Deepen Strategic Cooperation to Build a Hub for Biopharmaceutical Innovation

The first special loan of the "Yi Enterprise Win Win Plan" has been implemented to accelerate the industrialization process of innovative drugs
2025/01/08“Creating Excellent Drugs, Forging a Legacy!” DiQi Pharma Recognized as a National High-Tech Enterprise for the Fourth Time

On January 3, 2025, Guangzhou DiQi Pharmaceuticals Co., Ltd. was once again recognized as a National High-Tech Enterprise. The filing announcement has been published on the National High-Tech Enterprise Work Network.
2024/07/08China’s First Generic! DiQi Pharma’s Pregabalin Orally Disintegrating Tablets Approved for Market

On June 28, 2024, DiQi Pharmaceuticals Co., Ltd.'s independently developed Class 3 chemical drug—Prelibrin Orally Disintegrating Tablets—successfully received marketing approval! As DiQi Pharmaceuticals Co., Ltd.'s first MAH (Marketing Authorization Holder) product, Prelibrin Orally Disintegrating Tablets signifies a solid step forward in DiQi Pharmaceuticals Co., Ltd.'s transition from drug R&D to commercialization, marking a significant milestone in the company's development.
2024/01/21Dive In and Discover the Fascinating World of Biopharmaceuticals

On January 19, a group of high school students from Guangzhou visited DiQi Pharma for a tour and discussion session.
2023/11/02Great News! DiQi Pharma Honored on Guangzhou's First List of Top 100 Emerging Enterprises

Recently, the Guangzhou Municipal Bureau of Industry and Information Technology announced the list of Guangzhou's first 100 emerging enterprises, with Guangzhou DiQi Pharma honored to be included on the list.
2023/10/27DiQi Pharma Conducts 2023 Annual Fire Drill Activity

Autumn brings clear skies and crisp air, with dry conditions making it a peak season for fire incidents. On October 27, the Safety Production Committee of DiQi Pharma organized its annual fire safety training and drill. Professionals from the Security Department and Fire Department of Bio Island Property Management were specially invited to conduct on-site instruction and safety drills at the company.

1 2 3 4 5

Contact Information

Address:8 Luoxuan 3rd Road, Guangzhou International BIO-island

Main telephone number:020-32227031

Fax:020-32227031

Email:gzdq@gzdqyy.com
Customer Service

Postal Code:510300

Business Consulting:18122367150 13602749876

Complaints Hotline:020-32227031

Complaint Email:diqiyjx@gzdqyy.com

Official WeChat

top